Merck Shares Seek a Foundation Amid Diverging Business Fortunes

Merck shares fall to annual low as Mavenclad patent loss overshadows strong AI-driven electronics growth. Analysts see significant upside from current levels.

Shares of German science and technology giant Merck opened the week by touching a new annual low, struggling to hold the €104 level. The stock's decline has widened the gap between its current market price and the significantly higher targets set by equity analysts. This pressure stems from a clash between two corporate narratives: robust growth in electronics driven by artificial intelligence demand, and a substantial legal setback for a key pharmaceutical product.

Electronics and Life Sciences Provide Counterbalance

Amid the overall share price weakness, two of Merck's three business sectors are demonstrating strength. The company's Electronics segment is experiencing a powerful tailwind from the burgeoning demand for AI applications, which has fueled need for its semiconductor materials. This division recently posted organic sales growth exceeding 8%. Simultaneously, the Life Science unit is showing signs of recovery, with an organic sales increase of 4% indicating that the industry-wide inventory reduction among its customers may have concluded. These positive performances are providing crucial stability to the group's overall results.

Healthcare Setback Weighs on Sentiment

The primary driver of the recent sell-off originates in Merck's Healthcare division. A U.S. appeals court invalidated key patents for the multiple sclerosis drug Mavenclad, a blockbuster therapy that generated €1.19 billion in revenue most recently. This ruling paves the way for competition from lower-cost generic versions in the critical U.S. market as early as this year. In response, company management has adjusted its outlook, anticipating a decline in profitability. The pre-exceptional EBITDA margin is now expected to fall to approximately 28.0%.

Market Experts Maintain Bullish Long-Term Views

Despite the near-term challenges in pharmaceuticals, numerous research firms maintain constructive ratings on Merck's equity, seeing substantial upside from current levels:

• JPMorgan analysts recommend "Overweight" with a price target of €150.
• Deutsche Bank has a "Hold" rating and a €132 target.
• Bernstein Research recently initiated coverage with a "Market Perform" assessment.
• The consensus price target among analysts stands at €141.87.

Technical and Valuation Context

Trading around €104, Merck's stock sits roughly 15% below its 50-day moving average of €122.14. The share price is currently testing its 52-week low of €103.60. From a technical perspective, the Relative Strength Index (RSI) reading of 24.3 signals the stock is in oversold territory. The critical question for investors is whether this combination of technical oversold conditions and fundamental undervaluation will be sufficient to catalyze a sustained recovery. The answer likely depends on the speed at which the vigorous growth in the chip materials business can offset the financial headwinds created by the Mavenclad patent loss.